Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q

Oncogene

Volumn 25, Issue 18, 2006, Pages 2685-2696

  Lindgren, D ^a   Liedberg, F ^a   Andersson, A ^a   Chebil, G ^b   Gudjonsson, S ^a   Borg, A ^a   Mansson W ^a   Fioretos, T ^a   Hoglund M ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Chromosome 9; Expression profiling; FGFR3; Urothelial carcinoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53; RNA;

ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; CHROMOSOME 17P; CHROMOSOME 9Q; CHROMOSOME LOSS; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MICROSATELLITE MARKER; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UROGENITAL TRACT TUMOR;

CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 33646359953     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209249     Document Type: Article

References (39)

1. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L et al. (2003). Cancer Res 63: 8108-8112.
2. Baud E, Catilina P, Bignon YJ. (1999). Int J Oncol 14: 441-445.
3. Belkin AM, Stepp MA. (2000). Microsc Res Tech 51: 280-301.
4. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B et al. (2001). Am J Pathol 158: 1955-1959.
5. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K et al. (2005). Clin Cancer Res 11: 4044-4055.
6. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA et al. (2002). Eur Urol 41: 523-531.
7. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X et al. (1999). Nat Genet 23: 18-20.
8. Cordon-Cardo C. (1998). Cancer Surv 32: 115-131.
9. Duggan B, Williamson K. (2004). Curr Opin Urol 14: 277-286.
10. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K et al. (2004). Cancer Res 64: 4040-4048.
11. Dyrskjøt L, Thykjaer T, Kruhøffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S et al. (2003). Nat Genet 33: 90-96.
12. Dyrskjøt L, Zieger K, Kruhøffer M, Thykjaer T, Jensen JL, Primdahl H et al. (2005). Clin Cancer Res 11: 4029-4036.
13. Hafner C, Knuechel R, Stoehr R, Hartmann A. (2002). Int J Cancer 101: 1-6.
14. Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. (1999). BJU Int 83: 957-963.
15. Herr HW. (2000). J Urol 163: 60-61; discussion 61-62.
16. Heyer LJ, Kruglyak S, Yooseph S. (1999). Genome Res 9: 1106-1115.
17. Höglund M, Säll T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. (2001). Cancer Res 61: 8241-8246.
18. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M et al. (2005). Lab Invest 85: 532-549.
19. Knowles MA. (1999). Electrophoresis 20: 269-279.
20. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H et al. (2004). Clin Cancer Res 10: 3410-3421.
21. Mor O, Nativ O, Stein A, Novak L, Lehavi D, Shiboleth Y et al. (2003). Oncogene 22: 7702-7710.
22. Mostofi FK, Davies CJ, Sesterhenn I. (1999). Histological Typing Of Urinary Bladder Tumors. International Classification Of Tumors, 2nd edn. Springer: Berlin.
23. Prout GRJ, Barton BA, Griffin PP, Friedell GH. (1992). J Urol 148: 1413-1419.
24. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H et al. (1998). Am J Pathol 153: 1615-1621.
25. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. (2002). Genome Biol 3: SOFTWARE0003.
26. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al. (2003). Biotechniques 34: 374-378.
27. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ et al. (2003). Am J Pathol 163: 505-516.
28. Sobin LH, Wittekind CL. (2002). TNM Classification Of Malignant Tumors, 6th edn. John Wiley & Sons: New York.
29. Spruck III CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC et al. (1994). Cancer Res 54: 784-788.
30. Thykjaer T, Workman C, Kruhøffer M, Demtroder K, Wolf H, Andersen LD et al. (2001). Cancer Res 61: 2492-2499.
31. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. (2005). Blood 105: 2941-2948.
32. Tusher VG, Tibshirani R, Chu G. (2001). Proc Natl Acad Sci USA 98: 5116-5121.
33. Vajo Z, Francomano CA, Wilkin DJ. (2000). Endocr Rev 21: 23-39.
34. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC et al. (2004). Cancer Res 64: 1911-1914.
35. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP et al. (2002). Eur J Hum Genet 10: 819-824.
36. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC et al. (2003). J Clin Oncol 21: 1912-1921.
37. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. (1998). Cell 94: 625-634.
38. Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D et al. (2005). Clin Cancer Res 11: 4415-4429.
39. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J et al. (2002). Nucleic Acids Res 30: e15.